An open phase II, multicentre study of ABR-214936 [anatumomab mafenatox] in patients with advanced renal cell carcinoma
Latest Information Update: 05 May 2006
At a glance
- Drugs Anatumomab mafenatox (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 05 May 2006 New trial record.